Alaunos Therapeutics, Inc. (TCRT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Alaunos Therapeutics, Inc. (TCRT) closed at USD 2.07 on 2026-10-14, a change of -23 % over the past year, with a market capitalization of USD 6.38M.

Alaunos Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Alaunos Therapeutics, Inc. key figures

Previous close

USD 2.07 (2026-10-14)

1-year change

-23 %

Market cap

USD 6.38M

Enterprise value

USD 5.41M

P/E ratio (trailing)

-1.24

P/E ratio (forward)

-3.63

EPS (trailing)

-1.76

EPS (forward)

-0.60

PEG ratio

0.58

Price to book

8.32

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.00

Employees

1

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Alaunos Therapeutics, Inc. and compare it with other stocks.